Categories AlphaGraphs, Consumer, Earnings

SJM Infographic: Highlights of J.M. Smucker’s Q4 2023 report

The J.M. Smucker Co. (NYSE: SJM) on Tuesday announced fourth-quarter 2023 financial results, reporting an increase in adjusted profit and net sales.

The J.M. Smucker Q4 2023 earnings infographic

At $2.23 billion, fourth-quarter sales were up 10% year-over-year, reflecting higher sales across all key business divisions.

As a result, adjusted earnings, excluding special items, increased 18% annually to $2.64 per share. On a reported basis, it was a net loss of $600.7 million or $5.69 per share in Q4, compared to a net profit of $202.1 million or $1.87 per share last year.

Mark Smucker, the company’s chief executive officer, said, “Looking ahead to fiscal year 2024, we are focusing on sustaining our business momentum by investing in growth platforms, such as Uncrustables sandwiches and Milk-Bone dog treats, and supporting our talented employees whose hard work and dedication have been instrumental to our success.”

Prior Performance

  • JM-Smucker-Q2-2023-Earnings-Infographic
  • JM-Smucker-Q1-2023-Earnings-Infographic
  • JM Smucker Q4 2022 Earnings Infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight